Bitte haben Sie einen Moment Geduld, wir legen Ihr Produkt in den Warenkorb.
Bitte haben Sie einen Moment Geduld, wir legen Ihr Produkt in den Warenkorb.
| ISBN | 9781646475254 |
|---|---|
| Sprache | Englisch |
| Erscheinungsdatum | 26.09.2023 |
| Größe | 279 x 216 mm |
| Verlag | Hayle Medical |
| Herausgegeben von | Megan Durham |
| Lieferzeit | Lieferung innerhalb von 28 Werktagen |
| Herstellerangaben | Anzeigen Libri GmbH Europaallee 1 | D-36244 Bad Hersfeld gpsr@libri.de |
Tuberculosis (TB) refers to a type of infectious disease generally caused by Mycobacterium tuberculosis. Lungs are the primary target of this disease, but it can also affect the other parts of the body. It can be treated with a combination of antibacterial medications. However, the evolution of drug-resistant tuberculosis necessitates the development of effective, novel and safe drug regimens. Drug discovery and development is a difficult, expensive and time-consuming process. One of the popular frameworks used in drug discovery is model-informed drug discovery and development (MID3). It aims to provide an informative prediction of drug efficacy and exposure in people for choosing innovative anti-tuberculosis drug combinations. This book is compiled in such a manner, that it will provide in-depth knowledge about drug discovery for treating tuberculosis. Those with an interest in this area of pharmaceutical science would find it helpful.
| ISBN | 9781646475254 |
|---|---|
| Sprache | Englisch |
| Erscheinungsdatum | 26.09.2023 |
| Größe | 279 x 216 mm |
| Verlag | Hayle Medical |
| Herausgegeben von | Megan Durham |
| Lieferzeit | Lieferung innerhalb von 28 Werktagen |
| Herstellerangaben | Anzeigen Libri GmbH Europaallee 1 | D-36244 Bad Hersfeld gpsr@libri.de |
Wie gefällt Ihnen unser Shop?